XML 34 R22.htm IDEA: XBRL DOCUMENT v3.22.2
Liabilities Related to Sales of Future Royalties (Tables)
 6 Months Ended
Jun. 30, 2022
Other Liabilities Disclosure [Abstract]  
Schedule of Purchase and Sale Agreement
In 2012 and 2020, we sold to RPI Finance Trust (RPI) and entities managed by Healthcare Royalty Management, LLC (collectively, HCR), respectively, our rights to receive royalties under our license and manufacturing agreements with certain pharmaceutical partners as summarized below under the 2012 Purchase and Sale Agreement and the 2020 Purchase and Sale Agreement, respectively:
DrugManufacturerCounterparty under Purchase and Sale AgreementDate Sold
ADYNOVATE® and ADYNOVI® (brand name for ADYNOVATE® in Europe)
Takeda Pharmaceutical Company LimitedHealthcare Royalty Management, LLCDecember 16, 2020
MOVANTIK® (naloxegol tablets) and MOVENTIG® (brand name for MOVANTIK® in Europe)
AstraZeneca ABHealthcare Royalty Management, LLCDecember 16, 2020
REBINYN®
Novo Nordisk Inc., Novo Nordisk A/S and Novo Nordisk A/GHealthcare Royalty Management, LLCDecember 16, 2020
CIMZIA® (certolizumab pegol)
UCB PharmaRPI Finance TrustFebruary 24, 2012
MIRCERA® (Continuous Erythropoietin Receptor Activator)
F. Hoffmann-La Roche LtdRPI Finance TrustFebruary 24, 2012
Schedule Of Liability Related To Sale Of Potential Future Royalties
The following table shows the activity within the liability account of each arrangement (in thousands):
 
Period from inception to June 30, 2022
 
2012 Purchase and Sale Agreement2020 Purchase and Sale AgreementTotal
Royalty monetization proceeds$124,000 $150,000 $274,000 
Non-cash royalty revenue(297,507)(69,770)(367,277)
Non-cash interest expense229,474 29,556 259,030 
Payments to RPI(10,000)— (10,000)
Loss on revaluation of liability related to the sale of future royalties (1)23,522 — 23,522 
Liabilities related to the sales of future royalties – ending balance69,489 109,786 179,275 
Less: unamortized transaction costs— (2,500)(2,500)
Liabilities related to the sales of future royalties, net$69,489 $107,286 $176,775 
(1) Loss recognized from Settlement Agreement to resolve UCB’s challenges to our patents, as agreed to by UCB, RPI and us, on October 13, 2021.